INTRODUCTION
Corticotrophin-releasing factor-41 (CRF), arginine vasopressin (AVP) and in some studies oxytocin have been found to stimulate the release of adrenocorticotrophin (ACTH) which, in turn, results in the release of adrenal corticosteroids (Gillies, Linton & Lowry, 1982; Plotsky, 1985; Antoni, 1986) . CRF-, AVP-and oxytocin-synthesizing neurones are localized in the hypothalamus, with CRF and AVP neurones in the parvocellular division of the paraventricular nucleus (PVN) (Kiss, Mezey & Skirboll, 1984; Sawchenko & Swanson, 1984; Kovacs, Kiss & Makara, 1986; Sawchenko, 19876) , and AVP, as well as oxytocin expressed in magnocellular neurones of the supraoptic nucleus (SON) and PVN (Plotsky, 1985; Mohr, Bahnsen, Kissling & Richter, 1988) . Information about the intracellular regulation of synthesis and release of CRF, AVP and oxytocin is limited because of the lack of suitable in-vitro models.
Synaptic and hormonal inputs play important roles in CRF, AVP and oxytocin expression (Renaud, 1987;  Calogero, Bernadini, Gold & Chrousos, 1988a;  Baldino, O'Kane, Fitzpatrick-McElligott & Wolfson, 1988; Oeding, Schilling & Schmale, 1990) . These extracellular stimuli presumably affect the second intracellular messenger systems and may result in activation of adenylate cyclase activity and changes in intracellular levels of cyclic AMP (cAMP), or acceler¬ ate the hydrolysis of membrane inositol phospholipids and the activation of protein kinase C (PKC) (Hill & Kendall, 1989) . At present there is no evidence to suggest which second-messenger systems may be involved in the response to extracellular stimulation. Using a primary neonatal hypothalamic cell culture system, it has been reported that forskolin, a cAMP stimulator, and TPA (phorbol ester 12-0-tetradecanoyl-phorbol-13-acetate), a PKC stimulator, stimulated CRF release (Widmaier, Lim & Vale, 1989) . More recently, Emanuel, Girard, Thull & Majzoub (1990) reported that TPA and forskolin induced CRF gene expression of hypothalamic cells in culture. The treatment of cultured hypothalamic cells with forskolin or 3-isobutyl-l-methylxanthine (IBMX) resulted in an increase in AVP mRNA levels and in the numbers of AVP mRNA-positive cells, but had no effect on oxytocin mRNA expression (Oeding et al. 1990 ). In-vitro studies using an osmotic stimulus resulted in increased mRNA for the Gsa and Gia subunits of guanine nucleotide-binding proteins which regulate adenylate cyclase in magnocellular vasopres¬ sin and oxytocin cells (Young, Shepard & Burch, 1987) .
Adrenalectomy induces increased CRF and AVP immunostaining in the PVN and the synthesis of CRF peptide (Kovacs et al. 1986; Sawchenko, 1987 ) . The concentration of AVP in the hypothalamohypophysial portal blood is also increased after adrenalectomy (Eckland, Todd & Lightman, 19886) .
The induced CRF and AVP immunostaining and pep¬ tide release after adrenalectomy could be suppressed with glucocorticoid replacement (Kovacs et al. 1986; Eckland et al. 19886 ). Adrenalectomy and dexamethasone treatment do not affect portal oxytoxcin release (Fink, Robinson & Tannahill, 1988; Eckland et al. 19886 ), but Sapolsky, Armanini, Packan et al. (1990) (Ackland, Ratter, Bourne & Rees, 1986 ) was used at a final dilution of 1:48 000. Tyr-CRF-41 iodinated with 125I using the chloramine-T method was used for the assay. Antiserum and radiolabelled CRF were diluted in the radioimmunoassay buffer (50 mmol phosphate/1, pH 7-4, containing 0-25% (w/v) human serum albumin, 0-1% (v/v) 2-mercaptoethanol, 0-1% (v/v) Triton X-100). Radiolabelled CRF was added after 48 h of preincubation of first antibody and standards or samples. Incubation was continued for a further 24 h. Antibody-bound radiolabelled CRF was separated from the unbound by the addition to each tube of 50 pi sheep anti-rabbit serum followed by 0-5 ml 4% (w/v) aqueous polyethy¬ lene glycol. After incubation for 1 h at 4°C, tubes were centrifuged at 3000 ¿» for 1 h and the pellets counted for radioactivity. The intra-and interassay coefficients of variation were 6-8% and 15-3% respectively. The assay sensitivity was 2 pg/tube. Radioimmunoassay of AVP AVP was measured using the method described by Williams, Carter & Lightman (1985) with some modi¬ fications. The medium samples for the assay were not extracted. The assay was carried out using 100 pi of each of the following: the first international standard for AVP dissolved in culture medium, 125I-labelled AVP (4000-5000 c.p.m.), and specific AVP antiserum at a final dilution of 1:300 000. Radiolabelled AVP was added after a 24 h preincubation with antibody and standards or samples. Incubation was continued for a further 24 h. Antibody-bound radiolabelled AVP was separated from the free fraction by precipi¬ tation with chilled ethanol, centrifuging at 2500# for 15 min and decanting the supernatant. The pellets were counted for radioactivity. Assay sensitivity was 0125 pg/tube. The intra-and interassay coefficients of variation were 5-3 and 13% respectively.
Radioimmunoassay of oxytocin
Oxytocin was measured by the method described by Williams et al. (1985) with some modifications. The measurements were carried out using 100 pi each of the following: the fourth international standard for oxytocin dissolved in medium, l25I-labelled oxytocin (4000-5000 c.p.m.), and specific oxytocin antiserum at a final dilution of 1:450 000. Antibody-bound radiolabelled oxytocin was separated from the free fraction by precipitating with chilled ethanol, centrifuging at 2500 # for 15 min and decanting the supernatant. The pellets were counted for radioactivity. The intraand interassay coefficients of variation were 8 and 15% respectively. The sensitivity of the assay was 0-125-0-25 pg/tube.
High-pressure liquid chromatography (HPLC)
For the HPLC characterization of CRF, AVP and oxytocin released from the cultured fetal hypothala¬ mic cells, the culture media were collected and extracted on C,8-silica cartridges (SepPak; Millipore U.K., Harrow, Middx., U.K.) as previously described (Williams et al. 1985) . After (Fig. 1) .
Effects of PMA and forskolin Treatment of hypothalamic cultures with forskolin increased CRF, AVP and oxytocin release two-to fourfold (Fig. 2) . CRF, AVP and oxytocin release was also stimulated by PMA in a dose-dependent manner (Fig. 3) .
Effects of dexamethasone and aldosterone on the basal release of CRF, AVP and oxytocin
The basal release of CRF from the cultured cells was reduced by all the concentrations of dexamethasone used (Fig. 4) (Fig. 4) . Similarly 1 pmol aldosterone/1 only inhibited basal CRF release and had no effect on AVP and oxytocin release (Fig. 5) . to forskolin stimulation (20 pmol/1) (Fig. 6) . In a simi¬ lar manner, different concentrations of aldosterone reduced the release of all peptides (Fig. 7) .
Effects of dexamethasone and aldosterone on PMAst¡mutated CRF, AVP and oxytocin release Dexamethasone and aldosterone both blocked PMAstimulated CRF release, but neither dexamethasone nor aldosterone had any effect on AVP and oxytocin responses to PMA treatment (Fig. 8) (Jones & Gillham, 1988) . In-vivo studies have shown that adrenal steroid administration reduced CRF and AVP release and either had no effect on oxytocin release (Fink et al. 1988; Eckland et al. 19886) or inhibited oxytocin release (Sapolsky et al. 1990 ).
Hormonal-and transmitter-stimulated CRF release from expiants in vitro have been shown to be inhibited by adrenal steroids (Calogero, Gallucci, There are two types of corticosteroid receptors in the rat brain, the mineralocorticoid receptor (type I) with higher affinity for corticosterone and aldosterone than dexamethasone, and the glucocorticoid receptor (type II) with higher affinity for dexamethasone than corticosterone and aldosterone (Reul & de Kloet, 1985; Evans & Arriza, 1989; Beaumont & Fanestil, 1983) . The negative feedback effects of adrenal steroids on CRF, AVP and oxytocin in the central nervous system has been well documented with respect to glucocorticoids (Kovacs et al. 1986; Sawchenko, 19876; Sapolsky et al. 1990 ). The (Moisan, Seckl & Edwards, 1990 (Duman, Strada & Enna, 1989; Robinson & Kendall, 1990) . On the other hand even high doses of gluco¬ corticoid could not inhibit the CRF mRNA response to stress in vivo (Harbuz, Nicholson, Gillham & Lightman, 1990 (Gillies et al. 1982; Plotsky, 1985; Antoni, 1986) , the brain has a compo¬ site mechanism of response to the negative feedback effects of adrenal steroids.
